What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Lerodalcibep-liga demonstrates moderate benefit over current care, with placebo-adjusted LDL-C reductions of 55% and 50% in two pivotal 52-week trials, and 59% in a 24-week trial for HeFH. However, the absence of definitive cardiovascular outcomes trial evidence limits the strength of the claim.
Does the economic case hold at the expected price? — Cost effectiveness
No cost-effectiveness analyses or ICER data are available in the public domain, which is critical for evaluating economic value and limits the ability to assess cost-effectiveness.
Is there quality-of-life evidence payers weigh? — Quality of life
There is a complete absence of HRQoL data or utility values reported in the pivotal trials or FDA documentation, which is a significant limitation for HTA assessment.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The safety profile is generally favorable, with injection-site reactions being the most common adverse event. Most adverse events reported were mild to moderate, and serious adverse events were comparable to placebo.
Was the drug compared against what payers expect? — Comparator Selection
Lerodalcibep-liga was compared against appropriate standards of care, including placebo and evolocumab, which are relevant comparators in the context of LDL-C lowering therapies.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population includes diverse geographic representation, but there are limitations in subgroup analyses and the overall representativeness of the population for broader EU5 and Japan contexts.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
The treatment can be integrated into existing care pathways as an add-on therapy to statins, which aligns with current clinical practice guidelines for managing hypercholesterolemia.
Are the wider system costs understood? — Resource Use and Cost Implications
There is a lack of data on direct medical costs and implementation costs, which are essential for understanding the broader resource implications of adopting this therapy.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is based on multiple rigorous Phase III RCTs with large sample sizes, although there are concerns regarding the variability in effect estimates based on analysis populations.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are significant uncertainties regarding the long-term effectiveness and economic impact of lerodalcibep-liga, particularly due to the absence of cost-effectiveness data and cardiovascular outcomes.
